Oxycodone News and Research

RSS

New issue from Annals of Internal Medicine

Prescriptions of some opioids, such as oxycodone, have increased significantly over the past decade. As long-term opioid therapy for chronic noncancer pain becomes more common, the deaths associated with opioids increase.

19 Jan 2010

Study examines how opioid overdose differs by prescribed dose for chronic pain conditions

More and more Americans with chronic pain not caused by cancer are taking medically prescribed opioids like Oxycontin (oxycodone) and Vicodin (hydrocodone). The January 19 Annals of Internal Medicine features the first study to explore the risk of overdose in patients prescribed opioids for chronic noncancer pain in general health care.

19 Jan 2010

Safety concerns of acetaminophen

The pain reliever acetaminophen is one of the safest and most effective drugs on the market. It's often recommended instead of aspirin as a day-to-day pain reliever because it's much easier on the stomach than other over-the-counter options and is considered safe when taken properly.

18 Jan 2010

Physicians fail to provide pain treatment for fear of prescription drug abuse

Millions of Americans with significant or chronic pain associated with their medical problems are being under-treated as physicians increasingly fail to provide comprehensive pain treatment - either due to inadequate training, personal biases or fear of prescription drug abuse.

5 Jan 2010

FREEDRUGCARD.US launches new Rx savings program to reduce prescription drug prices

If you are looking for the best way to save money on your prescription drugs then FREEDRUGCARD.US is your best option. The free prescription assistance drug card program is sponsored by a non-profit organization and was launched to help all Americans lower the cost of prescription drugs.

31 Dec 2009

Fitch Ratings announces Covidien rating outlook stable

Fitch Ratings has affirmed Covidien plc's (Covidien) ratings.

19 Dec 2009

BDSI's BEMA Buprenorphine Phase 2 study meets primary efficacy endpoint

BioDelivery Sciences International, Inc. announced that the primary efficacy endpoint was achieved in the Company’s Phase 2 pain study assessing the efficacy and safety of BEMA Buprenorphine. The positive results follow BDSI’s March 2009 announcement of favorable Phase 1 study results.

17 Dec 2009

Deaths from opioid use in Ontario have doubled, according to new study

Deaths from opioid use in Ontario have doubled-from 13.7 deaths per million residents in 1991 to 27.2 deaths per million residents in 2004-according to a new study led by physicians at St. Michael's Hospital and the Institute for Clinical Evaluative Sciences (ICES) in Toronto.

8 Dec 2009

Phosphagenics commences Phase 1B clinical trial of its oxycodone/TPM transdermal patch systems

Phosphagenics Limited today announced the initiation of a Phase 1B clinical trial for its patented oxycodone/TPM (Targeted Penetration Matrix) transdermal patch systems.

2 Dec 2009

QRxPharma commences Phase 3 pivotal trial of MoxDuo IR

QRxPharma Limited announced today, as part of its Phase 3 program, the initiation of a registration (also called pivotal) trial (Study 008) comparing efficacy and safety profiles of MoxDuo(TM)IR against component doses of morphine and oxycodone alone for the management of moderate to severe post-operative pain following bunionectomy surgery. The Company expects to complete dosing by close of Q2 2010.

30 Nov 2009

Study examines temporal association between media coverage and opioid-related deaths

Increases in deaths from opioid drugs such as OxyContin may be linked to the volume of coverage such deaths receive in the news, according to a study from Children's Hospital Boston and the University of North Carolina (UNC), Chapel Hill. The study compared patterns of opioid deaths and patterns of news coverage between 1999 and 2005, during which time mortality rates from opioid abuse doubled.

20 Nov 2009

FDA approves Covidien's Abbreviated New Drug Application for CII

Covidien, a leading global provider of healthcare products, today announced that its subsidiary, Mallinckrodt Inc., has received U.S. Food and Drug Administration (FDA) approval of its Abbreviated New Drug Application (ANDA) for Oral Transmucosal Fentanyl Citrate (CII).

31 Oct 2009

36 individuals in Kentucky face federal prescription pill charges

The U.S. Attorney's Office announced today that 36 individuals face various federal prescription pill charges as part of the largest drug sweep operation in Kentucky's history.

30 Oct 2009

Meda Pharmaceuticals introduces Onsolis for treating breakthrough cancer pain

Meda Pharmaceuticals Inc. today announced the launch of Onsolis(TM)(fentanyl buccal soluble film) in the U.S. for the management of breakthrough pain (BTP) in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

13 Oct 2009

QRxPharma signs contractual agreement with Patheon

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today a contractual agreement with Patheon to manufacture clinical supplies of QRxPharma's controlled release Dual-Opioid(TM) formulation (MoxDuo(TM)CR). MoxDuo(TM)CR is designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic).

12 Oct 2009

Nutra Pharma to launch prescription analgesic for severe chronic pain treatment

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription analgesic, Nyloxin Rx, for the treatment of severe (Stage 3) chronic pain.

7 Oct 2009

Opioid drugs may not be effective for osteoarthritis

Should you take opioid drugs for hip and knee pain caused by osteoarthritis? Probably not, suggests a new review of the best research on the subject.

7 Oct 2009

Scientists identify measures for reducing $2 billion healthcare burden from substance abuse

With substance abuse now accounting for one in 14 hospital admissions and generating billions in health care costs, leading scientists held a briefing on Capitol Hill today to present the evidence that we already have and the evidence we need in treating and preventing the use and abuse of alcohol, drugs and tobacco.

3 Oct 2009

Inspirion Delivery Technologies completes Pre-IND meeting with the FDA

Inspirion Delivery Technologies, LLC ("IDT") announced today that last week the Company completed a pre-investigational new drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) to determine the clinical and regulatory pathway to advance its abuse deterrent, extended release formulation of oxycodone.

30 Sep 2009

Controlled release pills and capsules with dose dumping tendency should be tested

Controlled release pills and capsules that show a tendency in the standard laboratory test toward "dose dumping" - releasing their medicine in a faster and potentially unsafe manner in patients who have consumed alcohol - should be withheld from the market until proven safe with testing in people. That's the conclusion of a review of existing studies in the September-October issue of ACS' Molecular Pharmaceutics, a bi-monthly journal.

24 Sep 2009